BED: Uma Combinação com Etoposide, Bleomicina e Cisplatinum Efetiva em Tumores Germinativos Não-Seminomatosos Disseminados de Testículo

• Autor(a) principal: Rabinowits, Milton
• Data de Publicação: 2023
• Outros Autores: Andrade, Carlos Augusto V. de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3222
• topic: Tumor de Testículo; Quimioterapia; Etoposide; Testis Tumors; Chemotherapy; Etoposide

A total of 21 patients (pts) with nonseminomatous germ cell tumors of testis have been treated from october 1981 to october 1983, with a drug combination (BED) using etoposide (VP16) substituted for vinblastine (VLB), in combination with bleomycin (BLM) and cisplatin (DDP), in order to decrease toxicity and get better results. Complete remission (CR) was obtained in 15 (71 %), and there was no residual disease at surgery, in 4 of the remaining 6pts, with a favorable response (FR) in 19 (90%); 14 pts (67%) have remained alive without disease (WD) for 12-48 months (median 26 months). Pts with minimal disease (5) presented 100% of CR without rela pse. Pts with moderate and advanced disease presented FR: 86 and 89%, with only 5/and 44 % remaining WD, respectively. Three pts presented lung toxicity in the group with DDP preceding BLM (16pts). There was no episode of leukopenic fever or mucositis and muscle pain so frequent with VLB. BED is less toxic, but change of the sequence, avoiding the use of DDP preceding BLM is necessary, in order to prevent new cases of BLM lung toxicity lts effectivity, similar to regimens with VLB, BLM and DDP recommend BED to pts with minimal disease, as well as to evaluate more effective combinations when dealing with poor prognosis disease.